Pancreatic Cancer Diagnostics Market By type of test, type of cancer, End-user and Geography. Key Players are Ambry Genetics (U.S), Abbott Laboratories, Inc. (U.S), AstraZeneca plc. (U.K), Eli Lilly and Company(U.S.), bioMeriux SA (France), Illumina, Inc.

Precision Business Insights (PBI) in its report titled “Pancreatic Cancer Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the pancreatic cancer diagnostic market revenue growth over forecast period.

The pancreatic cancer diagnostics market size was accounted for US$ XX Mn in 2018 and anticipated to account for US$ XX Mn by 2025. The market for pancreatic cancer diagnostics is expanding, due to increase in the consumption of alcohol and tobacco and changes in lifestyle. Moreover, high adoption of premium-priced drugs such as Abraxane injection and Gemzar to treat the pancreatic cancer boost the market. However, factors such as difficulty in diagnosis during the early stages, limited treatment options (especially when the disease has spread to other parts of the body), low success rates of clinical trials for anti-cancer drugs, and high cost associated with the treatment hamper the pancreatic cancer diagnostics market.

Pancreatic cancer diagnostics market segmented on the basis of test, type of cancer, end user, and geography.

Surgery and Chemotherapy Segment Expected to Dominate the Market

Based on treatment, the pancreatic cancer diagnostics market can be segmented into surgery, chemotherapy, radiation therapy, and targeted therapy. Surgery and chemotherapy segments are expanding at a more rapid pace than radiation therapy and targeted therapy segments. This is due to the better clinical outcome and it offers realistic chances for cure.

Read more Insights at https://precisionbusinessinsights.com/market-reports/global-pancreatic-cancer-diagnostics-market/

Hospitals Will Dominate the Revenue Share.

Based on end-user type, pancreatic cancer diagnostics market segmented into hospitals, clinics, and research institutes. The hospitals segment is expanding at a rate higher than the other two segments. This growth is attributable to preference by patients to obtain complete treatment and availability of advanced tools and expertise.

North America, Accounts for Major Revenue Share for Pancreatic Cancer Diagnostic Market

Precision Business Insights (PBI) pancreatic cancer diagnostic market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional analysis, North America hold the leading market share, due to associated with excessive alcohol use and gallstones. As estimated by SEER, 46,420 new pancreatic cancer cases were reported in the U.S. in 2014. Well-established health care infrastructure, demand for premium-priced drugs, and rapid marketing approvals of drugs boost the market in Europe. Multinational companies are making significant investments in developing economies in Asia to penetrate the untapped markets. Growing habit of smoking, improper diet, and genetics are major factors that drive the market in India. The Rest of the World includes the Middle East, Africa Changes in the medical practice, availability of a wide range of products, and increasing adoption of targeted therapies are likely to drive the pancreatic cancer diagnostics market in the region during the forecast period.

Strategic Collaborations Play Vital Role in Pancreatic Cancer Diagnostic Market

Key players implement various strategies to establish their footprint in the global market, thereby enhancing their sale and outreaching the customer. For instance, in October 2017 - Amgen and CytomX Therapeutics announced a strategic collaboration in immuno-oncology.

Request sample brochure of the report at https://precisionbusinessinsights.com/request-sample/?product_id=18280

Key player’s profiles in the report are Amgen Inc., Beckman Coulter, Biorad Laboratories Inc., Celgene Corporation, Clovis Oncology Inc., Eli Lilly, F. Hoffmann-La Roche, Genentech Inc., Ipsen Pharmaceuticals, Novartis International AG, and Pfizer, among others.

Detailed Segmentation

By Test Type

o Blood Tests
o Biopsy
o Biological Markers

By Cancer Type

o Adenocarcinoma
o Squamous carcinoma
o Adenosquamous carcinoma

By End-User Type

o Hospitals
o Oncology Institutes
o Diagnostic Centres

Geography

o North America
 U.S.
 Canada
o Europe
 Germany
 UK
 France
 Russia
 Spain
 Italy
 Rest of Europe
o Asia-Pacific
 China
 Japan
 India
 ASEAN
 Rest of Asia Pacific
o Latin America
 Brazil
 Mexico
 Argentina
 Chile
 Rest of Latin America
o Middle East and Africa
 South Africa
 Gulf Corporation Council Countries(GCCC)
 Rest of MEA

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact us
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com

This release was published on openPR.